Anxiety Prevalence in Lymphoma: A Systematic Review and Meta-Analysis
Objective: Hodgkin and non-Hodgkin lymphoma patients are at high risk of experiencing anxiety because the clinical processes and therapies they undergo produce strong adverse effects. In this review we discuss the prevalence of anxiety among these patients and examine the methods used for data colle...
Gespeichert in:
| Veröffentlicht in: | Health psychology 2020-07, Vol.39 (7), p.580-588 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 588 |
|---|---|
| container_issue | 7 |
| container_start_page | 580 |
| container_title | Health psychology |
| container_volume | 39 |
| creator | Vargas-Román, Keyla Díaz-Rodríguez, C. Lourdes Cañadas-De la Fuente, Guillermo A. Gómez-Urquiza, José Luis Ariza, Tania De la Fuente-Solana, E. Inmaculada |
| description | Objective: Hodgkin and non-Hodgkin lymphoma patients are at high risk of experiencing anxiety because the clinical processes and therapies they undergo produce strong adverse effects. In this review we discuss the prevalence of anxiety among these patients and examine the methods used for data collection, intervention frequency, types of instruments used to recognize anxiety, and data collection purposes, both in Hodgkin and non-Hodgkin lymphoma survivors and patients being treated or diagnosed with these diseases. Methods: This systematic review and meta-analysis of the literature was carried out using the following sources: PubMed, Scopus, LILACS, and PsycINFO. Results: The meta-analysis sample was n = 2,138 and the overall prevalence of anxiety was 19% (95% CI [12%, 25%]). According to the Egger test, there were no publication biases and no studies were eliminated after the sensitivity analysis. The I2 for the heterogeneity analysis was 92.6%. Conclusions: Hodgkin and non-Hodgkin lymphoma patients are vulnerable to suffering anxiety. It is important to focus on the psychological effect of anxiety during remission or current cancer treatments because they can affect patient outcomes. |
| doi_str_mv | 10.1037/hea0000869 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2384198887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2383211580</sourcerecordid><originalsourceid>FETCH-LOGICAL-a379t-937643efb42701bfed1a5a4ab89fb200b5d7190217f21534e304dd2bb49371d23</originalsourceid><addsrcrecordid>eNp90Utv1DAQB3CrArVL6aUfoIrEBYECHk8S29xWVXlIi1rxOFuTZKKmygs7KeTb49W2IHHAl7n85j_WjBDnIN-ARP32lknGZwp7JDZgUabagHwiNlJpkxaAeCKehXAXjbJ5fixOUClQutAbcbUdfrU8r8mN53vqeKg4aYdkt_bT7djTu2SbfF3DzD3NbZV84fuWfyY01MlnnindDtStoQ3PxdOGusBnD_VUfH9_9e3yY7q7_vDpcrtLCbWdU4u6yJCbMlNaQtlwDZRTRqWxTamkLPNag5UKdKMgx4xRZnWtyjKLnVArPBUvD7mTH38sHGbXt6HirqOBxyU4hSYDa4zRkb74h96Ni4__jSoDzAssUP5XoUEFkJu9enVQlR9D8Ny4ybc9-dWBdPsTuL8niPjiIXIpe67_0MedR_D6AGgiN4W1Ih9323GoFu95mPdhDq3Tbj_7N4MijUM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2383211580</pqid></control><display><type>article</type><title>Anxiety Prevalence in Lymphoma: A Systematic Review and Meta-Analysis</title><source>APA PsycARTICLES</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><creator>Vargas-Román, Keyla ; Díaz-Rodríguez, C. Lourdes ; Cañadas-De la Fuente, Guillermo A. ; Gómez-Urquiza, José Luis ; Ariza, Tania ; De la Fuente-Solana, E. Inmaculada</creator><contributor>Freedland, Kenneth E</contributor><creatorcontrib>Vargas-Román, Keyla ; Díaz-Rodríguez, C. Lourdes ; Cañadas-De la Fuente, Guillermo A. ; Gómez-Urquiza, José Luis ; Ariza, Tania ; De la Fuente-Solana, E. Inmaculada ; Freedland, Kenneth E</creatorcontrib><description>Objective: Hodgkin and non-Hodgkin lymphoma patients are at high risk of experiencing anxiety because the clinical processes and therapies they undergo produce strong adverse effects. In this review we discuss the prevalence of anxiety among these patients and examine the methods used for data collection, intervention frequency, types of instruments used to recognize anxiety, and data collection purposes, both in Hodgkin and non-Hodgkin lymphoma survivors and patients being treated or diagnosed with these diseases. Methods: This systematic review and meta-analysis of the literature was carried out using the following sources: PubMed, Scopus, LILACS, and PsycINFO. Results: The meta-analysis sample was n = 2,138 and the overall prevalence of anxiety was 19% (95% CI [12%, 25%]). According to the Egger test, there were no publication biases and no studies were eliminated after the sensitivity analysis. The I2 for the heterogeneity analysis was 92.6%. Conclusions: Hodgkin and non-Hodgkin lymphoma patients are vulnerable to suffering anxiety. It is important to focus on the psychological effect of anxiety during remission or current cancer treatments because they can affect patient outcomes.</description><identifier>ISSN: 0278-6133</identifier><identifier>EISSN: 1930-7810</identifier><identifier>DOI: 10.1037/hea0000869</identifier><identifier>PMID: 32212767</identifier><language>eng</language><publisher>United States: American Psychological Association</publisher><subject>Analysis ; Anxiety ; Anxiety Management ; Bias ; Cancer ; Clinical outcomes ; Data Collection ; Epidemiology ; High risk ; Human ; Intervention ; Lymphoma ; Meta-analysis ; Neoplasms ; Remission (Medicine) ; Sensitivity analysis ; Side effects ; Side Effects (Treatment) ; Suffering ; Survivors ; Systematic review</subject><ispartof>Health psychology, 2020-07, Vol.39 (7), p.580-588</ispartof><rights>2020 American Psychological Association</rights><rights>2020, American Psychological Association</rights><rights>Copyright American Psychological Association Jul 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a379t-937643efb42701bfed1a5a4ab89fb200b5d7190217f21534e304dd2bb49371d23</citedby><orcidid>0000-0002-8684-1817 ; 0000-0002-7517-9506 ; 0000-0001-9404-5725 ; 0000-0002-3012-3410 ; 0000-0003-3618-4035</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902,30976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32212767$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Freedland, Kenneth E</contributor><creatorcontrib>Vargas-Román, Keyla</creatorcontrib><creatorcontrib>Díaz-Rodríguez, C. Lourdes</creatorcontrib><creatorcontrib>Cañadas-De la Fuente, Guillermo A.</creatorcontrib><creatorcontrib>Gómez-Urquiza, José Luis</creatorcontrib><creatorcontrib>Ariza, Tania</creatorcontrib><creatorcontrib>De la Fuente-Solana, E. Inmaculada</creatorcontrib><title>Anxiety Prevalence in Lymphoma: A Systematic Review and Meta-Analysis</title><title>Health psychology</title><addtitle>Health Psychol</addtitle><description>Objective: Hodgkin and non-Hodgkin lymphoma patients are at high risk of experiencing anxiety because the clinical processes and therapies they undergo produce strong adverse effects. In this review we discuss the prevalence of anxiety among these patients and examine the methods used for data collection, intervention frequency, types of instruments used to recognize anxiety, and data collection purposes, both in Hodgkin and non-Hodgkin lymphoma survivors and patients being treated or diagnosed with these diseases. Methods: This systematic review and meta-analysis of the literature was carried out using the following sources: PubMed, Scopus, LILACS, and PsycINFO. Results: The meta-analysis sample was n = 2,138 and the overall prevalence of anxiety was 19% (95% CI [12%, 25%]). According to the Egger test, there were no publication biases and no studies were eliminated after the sensitivity analysis. The I2 for the heterogeneity analysis was 92.6%. Conclusions: Hodgkin and non-Hodgkin lymphoma patients are vulnerable to suffering anxiety. It is important to focus on the psychological effect of anxiety during remission or current cancer treatments because they can affect patient outcomes.</description><subject>Analysis</subject><subject>Anxiety</subject><subject>Anxiety Management</subject><subject>Bias</subject><subject>Cancer</subject><subject>Clinical outcomes</subject><subject>Data Collection</subject><subject>Epidemiology</subject><subject>High risk</subject><subject>Human</subject><subject>Intervention</subject><subject>Lymphoma</subject><subject>Meta-analysis</subject><subject>Neoplasms</subject><subject>Remission (Medicine)</subject><subject>Sensitivity analysis</subject><subject>Side effects</subject><subject>Side Effects (Treatment)</subject><subject>Suffering</subject><subject>Survivors</subject><subject>Systematic review</subject><issn>0278-6133</issn><issn>1930-7810</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNp90Utv1DAQB3CrArVL6aUfoIrEBYECHk8S29xWVXlIi1rxOFuTZKKmygs7KeTb49W2IHHAl7n85j_WjBDnIN-ARP32lknGZwp7JDZgUabagHwiNlJpkxaAeCKehXAXjbJ5fixOUClQutAbcbUdfrU8r8mN53vqeKg4aYdkt_bT7djTu2SbfF3DzD3NbZV84fuWfyY01MlnnindDtStoQ3PxdOGusBnD_VUfH9_9e3yY7q7_vDpcrtLCbWdU4u6yJCbMlNaQtlwDZRTRqWxTamkLPNag5UKdKMgx4xRZnWtyjKLnVArPBUvD7mTH38sHGbXt6HirqOBxyU4hSYDa4zRkb74h96Ni4__jSoDzAssUP5XoUEFkJu9enVQlR9D8Ny4ybc9-dWBdPsTuL8niPjiIXIpe67_0MedR_D6AGgiN4W1Ih9323GoFu95mPdhDq3Tbj_7N4MijUM</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Vargas-Román, Keyla</creator><creator>Díaz-Rodríguez, C. Lourdes</creator><creator>Cañadas-De la Fuente, Guillermo A.</creator><creator>Gómez-Urquiza, José Luis</creator><creator>Ariza, Tania</creator><creator>De la Fuente-Solana, E. Inmaculada</creator><general>American Psychological Association</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7RZ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PKEHL</scope><scope>PSYQQ</scope><scope>7QJ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8684-1817</orcidid><orcidid>https://orcid.org/0000-0002-7517-9506</orcidid><orcidid>https://orcid.org/0000-0001-9404-5725</orcidid><orcidid>https://orcid.org/0000-0002-3012-3410</orcidid><orcidid>https://orcid.org/0000-0003-3618-4035</orcidid></search><sort><creationdate>20200701</creationdate><title>Anxiety Prevalence in Lymphoma: A Systematic Review and Meta-Analysis</title><author>Vargas-Román, Keyla ; Díaz-Rodríguez, C. Lourdes ; Cañadas-De la Fuente, Guillermo A. ; Gómez-Urquiza, José Luis ; Ariza, Tania ; De la Fuente-Solana, E. Inmaculada</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a379t-937643efb42701bfed1a5a4ab89fb200b5d7190217f21534e304dd2bb49371d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Analysis</topic><topic>Anxiety</topic><topic>Anxiety Management</topic><topic>Bias</topic><topic>Cancer</topic><topic>Clinical outcomes</topic><topic>Data Collection</topic><topic>Epidemiology</topic><topic>High risk</topic><topic>Human</topic><topic>Intervention</topic><topic>Lymphoma</topic><topic>Meta-analysis</topic><topic>Neoplasms</topic><topic>Remission (Medicine)</topic><topic>Sensitivity analysis</topic><topic>Side effects</topic><topic>Side Effects (Treatment)</topic><topic>Suffering</topic><topic>Survivors</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vargas-Román, Keyla</creatorcontrib><creatorcontrib>Díaz-Rodríguez, C. Lourdes</creatorcontrib><creatorcontrib>Cañadas-De la Fuente, Guillermo A.</creatorcontrib><creatorcontrib>Gómez-Urquiza, José Luis</creatorcontrib><creatorcontrib>Ariza, Tania</creatorcontrib><creatorcontrib>De la Fuente-Solana, E. Inmaculada</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>APA PsycArticles®</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Psychology</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><jtitle>Health psychology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vargas-Román, Keyla</au><au>Díaz-Rodríguez, C. Lourdes</au><au>Cañadas-De la Fuente, Guillermo A.</au><au>Gómez-Urquiza, José Luis</au><au>Ariza, Tania</au><au>De la Fuente-Solana, E. Inmaculada</au><au>Freedland, Kenneth E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anxiety Prevalence in Lymphoma: A Systematic Review and Meta-Analysis</atitle><jtitle>Health psychology</jtitle><addtitle>Health Psychol</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>39</volume><issue>7</issue><spage>580</spage><epage>588</epage><pages>580-588</pages><issn>0278-6133</issn><eissn>1930-7810</eissn><abstract>Objective: Hodgkin and non-Hodgkin lymphoma patients are at high risk of experiencing anxiety because the clinical processes and therapies they undergo produce strong adverse effects. In this review we discuss the prevalence of anxiety among these patients and examine the methods used for data collection, intervention frequency, types of instruments used to recognize anxiety, and data collection purposes, both in Hodgkin and non-Hodgkin lymphoma survivors and patients being treated or diagnosed with these diseases. Methods: This systematic review and meta-analysis of the literature was carried out using the following sources: PubMed, Scopus, LILACS, and PsycINFO. Results: The meta-analysis sample was n = 2,138 and the overall prevalence of anxiety was 19% (95% CI [12%, 25%]). According to the Egger test, there were no publication biases and no studies were eliminated after the sensitivity analysis. The I2 for the heterogeneity analysis was 92.6%. Conclusions: Hodgkin and non-Hodgkin lymphoma patients are vulnerable to suffering anxiety. It is important to focus on the psychological effect of anxiety during remission or current cancer treatments because they can affect patient outcomes.</abstract><cop>United States</cop><pub>American Psychological Association</pub><pmid>32212767</pmid><doi>10.1037/hea0000869</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8684-1817</orcidid><orcidid>https://orcid.org/0000-0002-7517-9506</orcidid><orcidid>https://orcid.org/0000-0001-9404-5725</orcidid><orcidid>https://orcid.org/0000-0002-3012-3410</orcidid><orcidid>https://orcid.org/0000-0003-3618-4035</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-6133 |
| ispartof | Health psychology, 2020-07, Vol.39 (7), p.580-588 |
| issn | 0278-6133 1930-7810 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2384198887 |
| source | APA PsycARTICLES; Applied Social Sciences Index & Abstracts (ASSIA) |
| subjects | Analysis Anxiety Anxiety Management Bias Cancer Clinical outcomes Data Collection Epidemiology High risk Human Intervention Lymphoma Meta-analysis Neoplasms Remission (Medicine) Sensitivity analysis Side effects Side Effects (Treatment) Suffering Survivors Systematic review |
| title | Anxiety Prevalence in Lymphoma: A Systematic Review and Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T03%3A46%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anxiety%20Prevalence%20in%20Lymphoma:%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=Health%20psychology&rft.au=Vargas-Rom%C3%A1n,%20Keyla&rft.date=2020-07-01&rft.volume=39&rft.issue=7&rft.spage=580&rft.epage=588&rft.pages=580-588&rft.issn=0278-6133&rft.eissn=1930-7810&rft_id=info:doi/10.1037/hea0000869&rft_dat=%3Cproquest_cross%3E2383211580%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2383211580&rft_id=info:pmid/32212767&rfr_iscdi=true |